News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
105,998 Results
Type
Article (6626)
Company Profile (13)
Press Release (99359)
Section
Business (41609)
Career Advice (385)
Deals (7395)
Drug Delivery (56)
Drug Development (10014)
Employer Resources (33)
FDA (1795)
Job Trends (1964)
News (60283)
Policy (4407)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
2026 Genetown Elite (1)
Academia (278)
Accelerated approval (1)
Adcomms (4)
Allergies (9)
Alliances (6044)
ALS (9)
Alzheimer's disease (170)
Antibody-drug conjugate (ADC) (21)
Approvals (1783)
Artificial intelligence (44)
Autoimmune disease (8)
Automation (2)
Bankruptcy (72)
Best Places to Work (1559)
BIOSECURE Act (3)
Biosimilars (19)
Biotechnology (12)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (45)
Cancer (291)
Cardiovascular disease (45)
Career advice (329)
Career pathing (3)
CAR-T (25)
Cell therapy (78)
Cervical cancer (3)
Clinical research (7992)
Collaboration (146)
Compensation (23)
Complete response letters (5)
COVID-19 (351)
CRISPR (5)
C-suite (83)
Cystic fibrosis (21)
Data (275)
Decentralized trials (1)
Denatured (2)
Depression (6)
Diabetes (124)
Diagnostics (883)
Digital health (6)
Diversity (1)
Diversity, equity & inclusion (12)
Drug discovery (29)
Drug pricing (55)
Drug shortages (21)
Duchenne muscular dystrophy (27)
Earnings (17584)
Editorial (18)
Employer branding (1)
Employer resources (31)
Events (11724)
Executive appointments (295)
FDA (1966)
Featured Employer (4)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Funding (159)
Gene editing (14)
Generative AI (3)
Gene therapy (56)
GLP-1 (484)
Government (664)
Grass and pollen (1)
Guidances (8)
Healthcare (3224)
Huntington's disease (3)
IgA nephropathy (4)
Immunology and inflammation (20)
Indications (2)
Infectious disease (372)
Inflammatory bowel disease (35)
Inflation Reduction Act (3)
Influenza (7)
Intellectual property (21)
Interviews (45)
IPO (3178)
IRA (19)
Job creations (438)
Job search strategy (296)
Kidney cancer (2)
Labor market (7)
Layoffs (76)
Leadership (2)
Legal (1120)
Liver cancer (8)
Lung cancer (32)
Lymphoma (17)
Management (9)
Manufacturing (79)
MASH (29)
Medical device (2409)
Medtech (2410)
Mergers & acquisitions (4363)
Metabolic disorders (371)
Multiple sclerosis (9)
NASH (7)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (244)
NextGen: Class of 2025 (1021)
Non-profit (453)
Northern California (434)
Now hiring (16)
Obesity (236)
Opinion (59)
Ovarian cancer (16)
Pain (20)
Pancreatic cancer (8)
Parkinson's disease (18)
Partnered (1)
Patents (42)
Patient recruitment (14)
Peanut (4)
People (17028)
Pharmaceutical (12)
Pharmacy benefit managers (8)
Phase I (2516)
Phase II (3683)
Phase III (2820)
Pipeline (250)
Podcasts (38)
Policy (47)
Postmarket research (211)
Preclinical (919)
Press Release (19)
Prostate cancer (17)
Psychedelics (10)
Radiopharmaceuticals (67)
Rare diseases (70)
Real estate (612)
Recruiting (16)
Regulatory (2984)
Reports (15)
Research institute (317)
Resumes & cover letters (51)
Rett syndrome (1)
RSV (4)
Schizophrenia (20)
Series A (43)
Series B (15)
Service/supplier (1)
Sickle cell disease (16)
Southern California (329)
Special edition (5)
Spinal muscular atrophy (19)
Sponsored (7)
Startups (616)
State (1)
Stomach cancer (1)
Supply chain (26)
Tariffs (4)
The Weekly (35)
United States (3608)
Vaccines (104)
Venture capitalists (13)
Webinars (5)
Weight loss (223)
Women's health (7)
Worklife (2)
Date
Today (24)
Last 7 days (156)
Last 30 days (542)
Last 365 days (6508)
2025 (1624)
2024 (6798)
2023 (7098)
2022 (9815)
2021 (9961)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (123)
Alabama (7)
Alaska (3)
Arizona (31)
Arkansas (5)
Asia (7044)
Australia (1131)
California (919)
Canada (435)
China (93)
Colorado (76)
Connecticut (52)
Delaware (21)
Europe (16084)
Florida (151)
Georgia (36)
Idaho (4)
Illinois (76)
India (5)
Indiana (83)
Iowa (1)
Japan (23)
Kansas (9)
Kentucky (2)
Louisiana (2)
Maine (5)
Maryland (186)
Massachusetts (603)
Michigan (31)
Minnesota (43)
Missouri (7)
Montana (13)
Nebraska (7)
Nevada (10)
New Hampshire (17)
New Jersey (438)
New Mexico (7)
New York (225)
North Carolina (179)
Northern California (434)
Ohio (41)
Oklahoma (3)
Oregon (4)
Pennsylvania (186)
Puerto Rico (4)
Rhode Island (6)
South America (188)
Southern California (329)
Tennessee (10)
Texas (161)
Utah (29)
Virginia (13)
Washington D.C. (10)
Washington State (49)
West Virginia (1)
Wisconsin (4)
105,998 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
·
2 min read
·
Tristan Manalac
Podcast
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; Novo Nordisk presents mixed results from oral semaglutide in cardiovascular disease; the EU’s Committee for Medicinal Products for Human Use declines to recommend Eli Lilly’s Alzheimer’s drug; and pharma R&D returns grew in 2024.
April 2, 2025
·
1 min read
·
Heather McKenzie
Obesity
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to
BioSpace
that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.
March 7, 2025
·
2 min read
·
Dan Samorodnitsky
Podcasts
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace
remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, Viking secures ample supply of its investigational obesity medication, J&J strikes out in depression, and Makary and Bhattacharya near confirmation.
March 12, 2025
·
1 min read
·
Heather McKenzie
Obesity
‘There’s Only One Semaglutide’: Novo CEO Admits Compounders Are Hurting Weight Loss Business
Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen on Thursday, but the company hopes to win patients over.
March 28, 2025
·
1 min read
·
Annalee Armstrong
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
GLP-1
Novo Launches DTC Program for Wegovy, Cutting Price to $499 a Month
Novo Nordisk’s NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less than half of its list price.
March 5, 2025
·
2 min read
·
Annalee Armstrong
Weight loss
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a mid-stage study.
March 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
December 19, 2024
·
1 min read
1 of 10,600
Next